Pfizer-Valneva Lyme vaccine shows strong protection but misses statistical bar
TL;DR Summary
An experimental Lyme vaccine from Pfizer and Valneva reduced the risk of Lyme disease by more than 70% in a trial, but it reportedly missed a key statistical endpoint, prompting regulators to scrutinize potential approval amid ongoing debates over trial methods and Lyme prevention.
- Pfizer’s Lyme vaccine shows efficacy, but misses key statistical hurdle statnews.com
- Lyme disease vaccine shows 70 percent efficacy, Pfizer says The Washington Post
- Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss CNBC
- Pfizer, Valneva blame low Lyme cases for phase 3 vaccine fail but still plan approval push Fierce Biotech
- Pfizer and French partner to seek approval for Lyme disease vaccine after late-stage trial MarketWatch
Reading Insights
Total Reads
0
Unique Readers
5
Time Saved
2 min
vs 3 min read
Condensed
91%
473 → 44 words
Want the full story? Read the original article
Read on statnews.com